From 9eb05b50ffd098f2bc8cadcfaf7cbcddb4a7a2b9 Mon Sep 17 00:00:00 2001
From: Liliana Sanfilippo <liliana.sanfilippo@uni-bielefeld.de>
Date: Sun, 29 Sep 2024 15:11:04 +0200
Subject: [PATCH] Auf Integrated Human Practice Seite -> Zeitstrahl:
Zeitmarken/Monate
---
src/data/hptimelinedata.tsx | 190 ++++++++++++++++++++++--------------
1 file changed, 116 insertions(+), 74 deletions(-)
diff --git a/src/data/hptimelinedata.tsx b/src/data/hptimelinedata.tsx
index eb46323d..bd5e5dc6 100644
--- a/src/data/hptimelinedata.tsx
+++ b/src/data/hptimelinedata.tsx
@@ -43,6 +43,7 @@ export interface TimelineDatenpunkt {
text?: string | Array<string> | Array<React.ReactNode>; /* Extra Text */
experton?: string;
summary: string;
+ months: string,
}
type StakeholderTag = 'Industry' | 'Academia' | 'Patient' | 'Medical Professional' | 'Milestone' | 'Other';
@@ -107,7 +108,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "",
implementation: "",
type: "meta",
- summary: ""
+ summary: "",
+ months: "February"
},
{
vorname: "Pitching ideas",
@@ -122,7 +124,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "",
implementation: "",
type: "meta",
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Ideation",
@@ -137,7 +140,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "",
implementation: "",
type: "meta",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "Prof. Dr.",
@@ -155,7 +159,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "X",
insights: "X",
implementation: "X",
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Max",
@@ -241,7 +246,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="Since you almost had to sue for your medication, do you know if there are any lawyers specializing in cases like this? " a="No, I don’t. " />
<QaBox q="Are most of the other patients you know in good health like you?" a="No. Another boy my age got a fungal infection and does not have long time left to live. " />
</>,
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "Prof. Dr.",
@@ -272,7 +278,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<li>Experimental Tools: Based on the discussion, we plan to use an Ussing chamber to measure overall CFTR function in different cell types but will also explore organoid-based approaches for preliminary testing. Additionally, we consulted the medical faculty on the possibility of using patch clamping for more detailed measurements of successful transfection and restored CFTR function. </li>
</ul>,
</p>],
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Exploring new ideas",
@@ -289,7 +296,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "",
implementation: "",
type: "meta",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "Dr.",
@@ -307,7 +315,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "",
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Looking for expertise",
@@ -323,7 +332,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "",
implementation: "",
type: "meta",
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Documenting progress",
@@ -339,7 +349,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "",
implementation: "",
type: "meta",
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Jan-Phillipp",
@@ -358,7 +369,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "The aim of the contact was to engage in a discussion about prime editing and pegRNAs, as the Jan-Phillip Gerhards had used these technologies in his internship. We sought to exchange ideas, gather insights, and explore potential improvements or strategies for our project, leveraging his experience with prime editing tools. His practical knowledge in this field was very valuable for refining our approach and ensuring we were aligned with the latest advancements and methodologies in prime editing. ",
insights: "During our discussion we gained valuable insights that had a significant impact on our project. One of the most important findings was the effectiveness of silent edits, which will enable us to make our PrimeGuide safer. Silent edits changes the sequence of bases in the DNA in such a way that the resulting protein remains unchanged, because the genetic code is redundant. This means that different codons can code for the same amino acid. By making silent edits in addition to correcting the CFTR gene, we can prevent the pegRNA from rebinding. We have also learned that the length of the primer binding site (PBS) plays a crucial role in determining optimal results and that it is recommended to keep the PBS temperature close to 37°C. Specifically, PBS lengths of 17nt (38.3°C) and 16nt (36.4°C) were found to be ideal options. For our planned set of 12 samples, it was recommended to use three different PBS lengths (differing by +/- 1nt from that close to 37°C) in combination with four RTTs to achieve the best result. Another important finding was the use of non-annotated regions with overhangs for cloning, which could give better results in our experiments. However, we also encountered concerns that circRNA, a covalently closed circular RNA molecule, might be sterically hindered by Cas9, which we need to investigate further. When discussing cloning overhangs, we learned that a base-pair length close to 60°C is optimal. However, the use of a 15nt PBS was not recommended as it has a lower temperature range which could affect performance. Although we still need to confirm the oligonucleotide delivery time, these findings will help us to refine our cloning strategy, optimise PBS selection and improve our overall approach to primer editing, especially in terms of the pegRNA design.",
implementation: "We incorporated the lessons learned from our discussions on prime editing and silent editing directly into our project by refining our approach to gene editing. Based on feedback about the optimal length of primer binding sequences (PBS) and RTTs, we adjusted the design of our pegRNAs to ensure greater precision and efficiency in our experiments. In particular, we learned that using PBS lengths close to 37°C melting temperatures (e.g. 16-17 nucleotides) increased stability, which led us to fine-tune these sequences for improved editing results. The concept of silent editing became an integral part of our safety strategy, allowing us to make changes to the DNA more precise. We also revised our cloning strategies by considering the appropriate overhang length, targeting a base pair length near the melting temperature of 60°C to improve cloning efficiency. We also reassessed the practicality of ordering shorter PBS sequences, concluding that lengths shorter than 15 nt were less advantageous due to reduced efficiency. By integrating these findings, we optimised our experimental workflow and made informed decisions about the tools and methods for our prime editing experiments. ",
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Katrin",
@@ -376,7 +388,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "The interview yielded valuable insights into the regular implementation of the therapy, the use of aids and the adaptation of exercises to the individual needs of the patients. It was notable that the therapy has improved considerably thanks to better medication and adapted exercises, with a concomitant increase in life expectancy for children affected by cystic fibrosis. Of particular interest was the emphasis on the importance of sport and exercise, which should not only be therapeutically effective, but also increase quality of life. ",
implementation: "The following statement by Katrin Westhoff had a particularly profound impact on our project: 'The more we know, the more opportunities we have.' We learned from the interview that the current medication is already helping many patients to a huge extent, but that there is still a significant opportunity for improvement. After all, successful gene therapy would markedly enhance the quality of life for those affected. The findings of this project will be disseminated to the relevant researchers in order to facilitate the rapid improvement of the quality of life of all cystic fibrosis patients, regardless of their mutation. ",
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/hp/katrin-westhoff-zoom.webp",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "Dr.",
@@ -462,7 +475,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
</>,
pictureurl_aim: "https://static.igem.wiki/teams/5247/photos/hp/interview-olariu.svg",
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/hp/olario-abbildung1.svg",
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Mattijs",
@@ -511,8 +525,9 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="For wild-type cells, you see a rapid and dramatic quenching because CFTR allows these ions to enter the cells. In cells with the mutation, there’s no quenching because the channel isn’t working. While it’s less relevant because these aren't patient cells, it’s closer to reality. The 16HBE cell line is an airway epithelial line, and the expression of CFTR is endogenous, so it’s not at the exaggerated levels you might see in more artificial models like HEK cells." a="Using the YFP assay could be a good alternative or a Plan B for getting a functional readout. This assay is medium to high throughput—you can run entire 96-well plates in about half an hour. All you need for this is the cells and a plate reader that can measure fluorescence and inject the buffer. If you don’t have a plate reader with an injection system, you can also manually add the buffer and quickly place the plate in the machine." />
<QaBox q="Yes, that sounds quite good. I think we’ll definitely consider that as a method." a="If you have a little more time, I wanted to ask about the pegRNA. You stabilized it with a stem loop or some kind of motif in the paper, like the trevopreQ1. Did you test other motifs as well, or...?" />
</>,
- references: <MattijsInterviewSources/> ,
- summary: ""
+ references: <MattijsInterviewSources />,
+ summary: "",
+ months: ""
},
{
vorname: "Nicole",
@@ -571,7 +586,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="Does research in genome medicine and gene therapies come from biology, medicine, or both?"
a="It’s mainly interdisciplinary. A lot of funding comes from industry, like BioNTech, or foundations like Mukoviszidose e.V., which funds research on cystic fibrosis. But in terms of practical research, it’s usually biologists or biotechnologists. Without industry support, research can struggle due to a lack of funding, so having backing is essential." />
</>,
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Katrin",
@@ -606,7 +622,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<p>Chrissi takes modulators and will soon take a trip to a water park with some friends. Katrin teaches us that when the children do not breathe out properly, air stays in the lungs and causes hyperinflation – with which it is actually harder to float in water! After the manual drainage, Katrin gets all of us glasses with water and dish soap and straws. Blowing bubbles is a playful way to train how to properly breathe out by either trying to blow bubbles as long as possible or trying to make an existing bubble as big as possible!</p>
</li>
</ol>,],
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Julia",
@@ -650,7 +667,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="Are there any restrictions for her in terms of physical activities?" a="No, not really. She does dancing once a week, physiotherapy, and she’s even done a swimming course without any problems." />
<QaBox q="How do you handle communicating about her illness?" a="We try not to make a big deal of it. When I looked for information, I found what we needed. There’s nothing we’ve really felt was missing." />
</>,
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Joshua",
@@ -694,8 +712,9 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
Especially in the context of Integrated Human Practices, it is important to examine both the positive and the negative to create a project with a
future. </p>],
pictureurl_interview: "",
- references: <JoshuaInterviewSources/>,
- summary: ""
+ references: <JoshuaInterviewSources />,
+ summary: "",
+ months: ""
},
{
title: "Prof. Dr.",
@@ -748,9 +767,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
Editing strategy. </p></>],
pictureurl_implementation: "https://static.igem.wiki/teams/5247/photos/for-wiki-texts/hp-patch-clamp/bild-patch-clamp-isi-oliver.webp",
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/for-wiki-texts/hp-patch-clamp/bild-interssierte-wissenschaftler-oho.webp",
- references: <WischmeyerSources/>,
- interview:
- <>
+ references: <WischmeyerSources />,
+ interview: <>
<QaBox q="Can you educate us about your academic career?" a="I did my doctorate 30 years ago at Bielefeld University and then worked at the Max Planck Institute in Göttingen a lot with the patch-clamp technique. Today, I’m head of the working group Cellular Neurophysiology of the medicine faculty of Bielefeld University." />
<QaBox q="What new methods are currently available in electrophysiological research?" a="One of the latest methods is E-cis measurements. These make it possible to examine a monolayer of confluent cells and to measure the membrane potential both above and below. The change in conductivity can be analyzed for instance as a function of CFTR expression." />
<QaBox q="How can we proceed with the investigation of CFTR in different cell cultures by patch-clamp?" a="You can study CFTR expression in HEK cells, which allows for a measurable change in chloride conductance. I am not sure whether we will be able to investigate CFTR sufficiently in epithelial cells which you want to collect from your CF patient friend and your team members. That is something we have to try out." />
@@ -760,8 +778,9 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="What requirements must be met for cultivation and transfection before the patch-clamp measurement?" a="You have to cultivate the cells on poly-lysine and laminin and use round coverslips of 10 mm diameter to prepare them for measurement. For identification of positive transfectants, we use GFP co-transfected cells in our working group, you should think of something like that as well. A transfection rate of 10 % is sufficient to gain enough cells for the measurement. You can think of optimizing your transfection by using Lipofectamine2000, which works well for our working group." />
<QaBox q="Who could help us with the patch-clamp measurements?" a="The patch-clamp devices are heavily utilized in our working group, so you probably cannot perform measurements on your own. However, postdocs could support you for some measurements. Dr. Oliver Dräger is available as a contact person of my working group." />
- </>,
- summary: "n summary, through the interview with Prof. Dr. Wischmeyer and the collaboration with his employee Dr. Oliver Dräger, we gained valuable insights and optimized our approach to effectively investigate and measure the functionality of the CFTR ion channel, thereby determining the efficiency of our prime editing strategy."
+ </>,
+ summary: "n summary, through the interview with Prof. Dr. Wischmeyer and the collaboration with his employee Dr. Oliver Dräger, we gained valuable insights and optimized our approach to effectively investigate and measure the functionality of the CFTR ion channel, thereby determining the efficiency of our prime editing strategy.",
+ months: ""
},
{
title: "Prof. Dr.",
@@ -780,7 +799,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "Dr.",
@@ -799,7 +819,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Svenja",
@@ -824,7 +845,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
</ul>
],
implementation: [<p>On the basis of Svenja’s and other opinions on the topic, we decided not to try implementing a PACE system. </p>],
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Max",
@@ -840,7 +862,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "",
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "Dr.",
@@ -858,7 +881,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "The aim of the interview was to get an answer to the question of whether we need an ethics vote for our project or not and to obtain guidelines for dealing with patient cells regarding ethical issues and data protection. ",
insights: "The discussion was very informative in terms of how we should approach this topic and focused primarily on the important factors that need to be considered when planning the handling of patient cells. These include which legal principles need to be observed, data protection, ethical considerations and, above all, detailed and specific information for the donor. It also made us look at the situation from many different angles and consider the risks of worst-case scenarios. Overall, this interview was very useful to us, and we were able to use the information we gained to develop a kind of guideline that allowed us to approach this sensitive topic, which was new to us, with a certain degree of confidence. ",
implementation: "Based on the knowledge we have gained, we have drawn up guidelines for our handling of the cells. We used this guide when handling the patient cells, to ensure they were handled in an ethically correct manner.",
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Collaboration",
@@ -875,7 +899,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "",
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Benjamin",
@@ -917,8 +942,9 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
pictureurl_aim: "https://static.igem.wiki/teams/5247/photos/hp/hp-rnhale-zoom.png",
pictureurl_interview: "https://static.igem.wiki/teams/5247/photos/for-wiki-texts/del-interview-rnhale/paper-overview.jpg",
pictureurl_implementation: "https://static.igem.wiki/teams/5247/photos/for-wiki-texts/del-interview-rnhale/paper-sem.jpg",
- references: <RnhaleSources/>,
- summary: ""
+ references: <RnhaleSources />,
+ summary: "",
+ months: ""
},
{
title: "XXX",
@@ -935,7 +961,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "",
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Steffen Bira and",
@@ -950,18 +977,19 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
language: "de",
quote: "X",
aimofcontact: [<p>The goal of the discussion with Steffen Bira and Serra Gürcan from Corden Pharma was to gain insight into the design, stability, and practical application of lipid nanoparticles (LNPs) for use in gene therapy. The conversation focused on the possibility of using Corden Pharma’s LNP starter kits, understanding the factors affecting the stability of LNPs, and exploring options for incorporating antibodies into LNPs to target specific cells. </p>],
- insights: [<p>Steffen Bira and Serra Gürcan of Corden Pharma[Link Corden Pharmahttps://cordenpharma.com/] indicated that our planned spray drying approach of LNPs has not been extensively explored within their operations. The company focuses primarily on the aseptic fill and finish of LNPs, particularly for injectable formulations. However, they acknowledged the potential for spray drying and recommended consulting with specialized companies to assess the feasibility.
- The stability of the lipids used in LNPs during the spray drying process was also identified as an area requiring further investigation.
- The stability of LNPs, in particular in the context of the shear forces encountered in inhalation therapy, was identified as a critical factor. Corden Pharma highlighted that while the stability of individual lipid components can be evaluated, the stability of a complete LNP formulation containing RNA or other payloads must be empirically tested. The company put forward the suggestion that cryoprotectants and varying temperature conditions might be considered to
- enhance the stability of LNPs during processing. Corden Pharma outlined the process used to select the lipids included in their LNP starter kits, nothing that these combinations are based on established interactions and research findings, particularly in RNA-containing formulations. The kits are designed to facilitate the creation of stable LNPs by providing materials that have been tested for their physical-chemical properties, encapsulation efficiency, and potency. Furthermore, the company highlighted that a single LNP starter kit can be used for multiple batches, offering a practical solution for experimental work.
- When asked about modifying lipid components within LNP formulations, Corden Pharma suggested that exploring alternative lipids and other components could be beneficial for improving stability and efficacy, depending on the specific needs of the project. We discussed the availability of various lipids, including derivatives of cholesterol, which might enhance transfection efficiency in certain cell types. Corden Pharma confirmed that it is also possible to incorporate antibodies into LNPs, either during the initial preparation phase or by incubating antibodies with formed LNPs to achieve surface localization.
- While they did not have hands-on experience in this specific application, they referenced existing studies that could provide further guidance.
- Corden Pharma clarified that their role as a Contract Development and Manufacturing Organization (CDMO) is focused on providing services
+ insights: [<p>Steffen Bira and Serra Gürcan of Corden Pharma[Link Corden Pharmahttps://cordenpharma.com/] indicated that our planned spray drying approach of LNPs has not been extensively explored within their operations. The company focuses primarily on the aseptic fill and finish of LNPs, particularly for injectable formulations. However, they acknowledged the potential for spray drying and recommended consulting with specialized companies to assess the feasibility.
+ The stability of the lipids used in LNPs during the spray drying process was also identified as an area requiring further investigation.
+ The stability of LNPs, in particular in the context of the shear forces encountered in inhalation therapy, was identified as a critical factor. Corden Pharma highlighted that while the stability of individual lipid components can be evaluated, the stability of a complete LNP formulation containing RNA or other payloads must be empirically tested. The company put forward the suggestion that cryoprotectants and varying temperature conditions might be considered to
+ enhance the stability of LNPs during processing. Corden Pharma outlined the process used to select the lipids included in their LNP starter kits, nothing that these combinations are based on established interactions and research findings, particularly in RNA-containing formulations. The kits are designed to facilitate the creation of stable LNPs by providing materials that have been tested for their physical-chemical properties, encapsulation efficiency, and potency. Furthermore, the company highlighted that a single LNP starter kit can be used for multiple batches, offering a practical solution for experimental work.
+ When asked about modifying lipid components within LNP formulations, Corden Pharma suggested that exploring alternative lipids and other components could be beneficial for improving stability and efficacy, depending on the specific needs of the project. We discussed the availability of various lipids, including derivatives of cholesterol, which might enhance transfection efficiency in certain cell types. Corden Pharma confirmed that it is also possible to incorporate antibodies into LNPs, either during the initial preparation phase or by incubating antibodies with formed LNPs to achieve surface localization.
+ While they did not have hands-on experience in this specific application, they referenced existing studies that could provide further guidance.
+ Corden Pharma clarified that their role as a Contract Development and Manufacturing Organization (CDMO) is focused on providing services
for the production of active pharmaceutical ingredients (APIs) and excipients, rather than developing therapeutic products. They advised that intellectual property (IP) considerations are crucial when selecting lipids for LNP formulations, especially in commercial applications, as many lipids are patented. Companies pursuing gene therapy projects should ensure that the lipids they choose are free from IP restrictions or be prepared to pay associated fees.
The possibility of establishing a collaborative relationship was discussed, with Corden Pharma open to the idea of offering discounts on LNP starter kits or other materials in exchange for recognition in publications or other forms of acknowledgment. This proposal is subject to internal approval and would be pursued further through direct communication. </p>],
- implementation: [<p>The cooperation with Cordon Pharma provided invaluable insights for the project, particularly regarding the selection of lipids critical LNP stability and the potential applications of LNPs in gene therapy. Our initial approach involved utilising the Cayman kit, which proved to be suboptimal for the intended delivery of our Primeguide. The Corden Pharma kit #2 offers enhanced delivery efficiency thanks to its cutting-edge lipid components, including cationic lipids that boost cellular uptake and auxiliary lipids
+ implementation: [<p>The cooperation with Cordon Pharma provided invaluable insights for the project, particularly regarding the selection of lipids critical LNP stability and the potential applications of LNPs in gene therapy. Our initial approach involved utilising the Cayman kit, which proved to be suboptimal for the intended delivery of our Primeguide. The Corden Pharma kit #2 offers enhanced delivery efficiency thanks to its cutting-edge lipid components, including cationic lipids that boost cellular uptake and auxiliary lipids
that reinforce the LNP structure. However, we have subsequently updated our approach and now use the Corden Pharma Kit, which builds on these benefits by including even more optimised lipid formulations. This change allows us to further improve the robustness and stability of our LNP formulations. The insights gained from the survey will significantly influence our testing process and enable us to optimise the delivery of therapeutic agents and improve overall treatment efficacy. </p>],
- summary: ""
+ summary: "",
+ months: ""
},
{
vorname: "Mattijs",
@@ -979,7 +1007,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "Dr.",
@@ -998,7 +1027,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "",
@@ -1015,7 +1045,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "",
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "",
@@ -1036,12 +1067,13 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
implementation: [<p>The next phase of developing a new hygiene concept is to maintain contact with Mr. Johannfunke in order to continue to advance the hygiene concept in collaboration. The strategic approach entails the incremental implementation of measures, exemplified by the establishment of the inaugural toilet facility within the main building. It is of the utmost importance to ensure the uninterrupted implementation of the hygiene concept. In order to achieve this, it is essential to draw upon the existing plans and measures that have already been implemented in new buildings. We are working on advancing the plans at a higher level and are in regular dialogue with the Central contact point Barrier-free in order to overcome bureaucratic hurdles and actively promote the topic. Furthermore, it is necessary to intensify lobbying work in order to gain greater support for this issue at both the university and political levels. </p>],
language: "de",
interview: <>
- <QaBox q="What do you think of our hygiene concept and our plan?" a="This is a very acute problem. It particularly affects students with disabilities and immune-compromised staff, such as those with cancer or cystic fibrosis, who are forced to work from home. The problem is: Employees can work from home, but students cannot. There is a great need for hygiene measures, as contact must be avoided to minimise the risk of infection."/>
- <QaBox q="What are the challenges in implementing the hygiene concept?" a="There is a lack of strategic development, although your hygiene concept is well developed. It is necessary to proceed in small steps, e.g. starting with a toilet in the main building. However, bureaucracy is a major obstacle. To be implemented, an application has to be submitted to the rectorate, and these processes are often lengthy and complicated."/>
- <QaBox q="What is the current situation at our university?" a="While some progress has been made with the installation of additional toilets and disabled-friendly toilets in new buildings, there is as yet no overarching strategy in place to guide future developments. Furthermore, the lack of clarity regarding the mission statement and objectives leaves room for ambiguity. The duty of care that employers have towards employees is established, yet the situation is regulated differently with regards to students. The possibility of receiving compensation for disadvantages is open, but is frequently seen as inadequate."/>
- <QaBox q="What are the next steps in implementing the hygiene concept?" a="It is essential that the concept be implemented in small, strategic steps. At the same time, it is vital that the rectorate and other decision-makers be consulted on a regular basis to ensure that this matter remains at the forefront of discussions. Furthermore, it is of great importance to engage in political lobbying to secure additional support for this issue."/>
- </>,
- summary: "We got in touch because there was an acute hygiene problem for particularly vulnerable groups like immunocomprised persons at the university. We learnt from the exchange that despite a well-developed hygiene policy, strategic steps are still needed, especially to overcome bureaucratic hurdles. We have integrated these lessons into our project by focusing on continuous collaboration with the Central contact point Barrier-free and other decision-makers."
+ <QaBox q="What do you think of our hygiene concept and our plan?" a="This is a very acute problem. It particularly affects students with disabilities and immune-compromised staff, such as those with cancer or cystic fibrosis, who are forced to work from home. The problem is: Employees can work from home, but students cannot. There is a great need for hygiene measures, as contact must be avoided to minimise the risk of infection." />
+ <QaBox q="What are the challenges in implementing the hygiene concept?" a="There is a lack of strategic development, although your hygiene concept is well developed. It is necessary to proceed in small steps, e.g. starting with a toilet in the main building. However, bureaucracy is a major obstacle. To be implemented, an application has to be submitted to the rectorate, and these processes are often lengthy and complicated." />
+ <QaBox q="What is the current situation at our university?" a="While some progress has been made with the installation of additional toilets and disabled-friendly toilets in new buildings, there is as yet no overarching strategy in place to guide future developments. Furthermore, the lack of clarity regarding the mission statement and objectives leaves room for ambiguity. The duty of care that employers have towards employees is established, yet the situation is regulated differently with regards to students. The possibility of receiving compensation for disadvantages is open, but is frequently seen as inadequate." />
+ <QaBox q="What are the next steps in implementing the hygiene concept?" a="It is essential that the concept be implemented in small, strategic steps. At the same time, it is vital that the rectorate and other decision-makers be consulted on a regular basis to ensure that this matter remains at the forefront of discussions. Furthermore, it is of great importance to engage in political lobbying to secure additional support for this issue." />
+ </>,
+ summary: "We got in touch because there was an acute hygiene problem for particularly vulnerable groups like immunocomprised persons at the university. We learnt from the exchange that despite a well-developed hygiene policy, strategic steps are still needed, especially to overcome bureaucratic hurdles. We have integrated these lessons into our project by focusing on continuous collaboration with the Central contact point Barrier-free and other decision-makers.",
+ months: ""
},
{
title: "Dr.",
@@ -1059,9 +1091,10 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: [<p>The objective of this contact was to gather further information about cystic fibrosis (CF) in Asia, with a particular focus on understanding potential data biases, identifying common mutations, exploring the available medications, and assessing the diagnostic practices in the region. </p>],
insights: [<p>The talk with Sriram revealed that, although cystic fibrosis (CF) is relatively uncommon in Asia compared to other disease like sickle cell disease, it nevertheless exhibits considerable genetic diversity. The identification of different mutations in the CFTR gene across the region has revealed that the F508del mutation is the most common, a finding that aligns with global patterns. However, in Asian populations, other rare mutations are also prevalent, which presents unique challenges in diagnosis and treatment.
Additionally, it was found that environmental factors, such as air pollution, serve to exacerbate the symptoms of CF, particularly in densely populated regions, thereby further complicating the management of the disease. This emphasises the necessity for further research on CF that is specifically tailored to the needs of different regions, including improvements in diagnostic techniques and the development of treatments that are more closely aligned with the characteristics of the populations in question. </p>],
- implementation: [<p>The data were incorporated by confirming that the F508del mutation is not only the most common in Europe but also globally, including in Asia, highlighting a broader perspective and contributing to a significant horizon expansion in understanding the mutation's worldwide prevalence. This finding lends support to the idea that existing therapies targeting the F508del mutation will be effective for many patients worldwide, thereby providing a solid foundation for treatment. As a starting point, this is promising, but future efforts will focus on adapting therapies to address other, rarer mutations found in specific populations.
- </p>],
+ implementation: [<p>The data were incorporated by confirming that the F508del mutation is not only the most common in Europe but also globally, including in Asia, highlighting a broader perspective and contributing to a significant horizon expansion in understanding the mutation's worldwide prevalence. This finding lends support to the idea that existing therapies targeting the F508del mutation will be effective for many patients worldwide, thereby providing a solid foundation for treatment. As a starting point, this is promising, but future efforts will focus on adapting therapies to address other, rarer mutations found in specific populations.
+ </p>],
summary: "The contact provided valuable insights into cystic fibrosis (CF) in Asia and confirmed that the F508del mutation is the most common, as it is globally. However, the genetic diversity observed in Asia, together with the exacerbation of symptoms by environmental factors such as air pollution, highlights the need for more region-specific research. Future efforts will focus on refining treatments for rarer mutations and improving diagnostic accuracy in Asian populations.",
+ months: ""
},
{
title: "",
@@ -1078,8 +1111,9 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: [<p>The aim of our contact with Philipp Kühnel, a PhD student from the Otorhinolaryngology working group of Bielefeld University, was to gain expertise in working with primary cultures, particularly focusing on air-liquid interface (ALI) cultures. Given his experience in this area, we sought his guidance to ensure that we were following best practices and to address any technical challenges we might encounter.</p>],
insights: [<p>Through our discussions with Philipp, we gained valuable insights into the optimal conditions for cultivating primary cells and maintaining ALI cultures. He provided practical advice on troubleshooting of common issues, such as cell differentiation and culture stability, which were crucial for the success of our experiments. We also maintained close contact to exchange information about fungi that frequently contaminate ALI cultures. The expertise shared on combating these fungal contaminations was particularly valuable and greatly enhanced our understanding of effective prevention and treatment methods. </p>],
implementation: [<p>We incorporated Philipp’s advice by refining our culture protocols, particularly adjusting the conditions for ALI cultures to improve cell differentiation and overall culture health. This directly enhanced the reliability of our experimental results, ensuring that our work with primary cultures was both accurate and reproducible. </p>],
- language:"de",
- summary: "The contact aimed to leverage Philipp’s expertise in ALI cultures to improve our experimental protocols Gained insights into optimizing conditions for primary cell cultures and managing common challenges like fungal contamination"
+ language: "de",
+ summary: "The contact aimed to leverage Philipp’s expertise in ALI cultures to improve our experimental protocols Gained insights into optimizing conditions for primary cell cultures and managing common challenges like fungal contamination",
+ months: ""
},
{
title: "",
@@ -1099,24 +1133,25 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
summary: "The interview focused on understanding the operations of the Biobank OWL, particularly in the areas of quality management and sample processing. Provided a detailed overview of biobank activities, including sample collection, storage conditions, and data protection measures",
language: "de",
interview: <>
- <QaBox q="Can you briefly explain to us what exactly a biobank is and what its main tasks are?"
- a="A biobank is a specialized facility that collects, stores, and manages biological samples and associated data for research purposes. Each biobank is unique in its operations and functions. In Bielefeld and Lippe, the Biobank BOWL (Biobank OWL) is responsible for the storage of patient samples. The Data Integration Centre (DIZ) stores data pertaining to these samples. A trustee oversees the pseudonymisation of data, acting as an interface between BOWL and DIZ, ensuring that patient data cannot be directly linked to patient samples." />
- <QaBox q="What types of samples are collected in your biobank and for what research purposes are they used?"
+ <QaBox q="Can you briefly explain to us what exactly a biobank is and what its main tasks are?"
+ a="A biobank is a specialized facility that collects, stores, and manages biological samples and associated data for research purposes. Each biobank is unique in its operations and functions. In Bielefeld and Lippe, the Biobank BOWL (Biobank OWL) is responsible for the storage of patient samples. The Data Integration Centre (DIZ) stores data pertaining to these samples. A trustee oversees the pseudonymisation of data, acting as an interface between BOWL and DIZ, ensuring that patient data cannot be directly linked to patient samples." />
+ <QaBox q="What types of samples are collected in your biobank and for what research purposes are they used?"
a="The biobank collects a wide variety of samples, including blood, stool, and soil. Samples may be gathered for specific research projects or for establishing a general repository under 'broad consent.' Researchers wishing to use these samples must apply to the 'use access committee,' which evaluates whether the requested samples and data can be released for their research." />
- <QaBox q="How large is your biobank? How many samples do you currently store and how many new samples are added on average?"
+ <QaBox q="How large is your biobank? How many samples do you currently store and how many new samples are added on average?"
a="The biobank is still in the process of establishing itself and has not yet reached its full sample capacity. However, it is anticipated to accumulate a significant number of samples in the near future, with several thousand samples expected to be analyzed in dedicated sessions." />
- <QaBox q="What requirements and criteria must be met for a sample to be included in your biobank?"a="Samples must be processed according to highly detailed protocols, and regular audits are conducted to ensure compliance with all standards." />
- <QaBox q="Which other research institutions or biobanks do you cooperate with and what form does this cooperation take?"
+ <QaBox q="What requirements and criteria must be met for a sample to be included in your biobank?" a="Samples must be processed according to highly detailed protocols, and regular audits are conducted to ensure compliance with all standards." />
+ <QaBox q="Which other research institutions or biobanks do you cooperate with and what form does this cooperation take?"
a="Biobank OWL has a second location in Lippe, in addition to Bielefeld. Collaborations exist with the DIZ, the Treuhand, and three university hospitals. It is anticipated that cooperation with other working groups will increase in the future." />
- <QaBox q="What specific storage conditions (e.g. temperature, humidity) must be observed for different sample types?"
+ <QaBox q="What specific storage conditions (e.g. temperature, humidity) must be observed for different sample types?"
a="Samples are stored under various temperature conditions, including -20°C, -80°C, and -150°C, along with the use of liquid nitrogen." />
- <QaBox q="How do you ensure that the samples remain stable and usable over longer periods of time?"
+ <QaBox q="How do you ensure that the samples remain stable and usable over longer periods of time?"
a="Samples are stored in nitrogen for long-term stability." />
- <QaBox q="What encryption techniques or data protection measures are used in your biobank to prevent unauthorized access to patient data? Are there special regulations for the anonymisation of data and how is it ensured that patients cannot be traced?"
+ <QaBox q="What encryption techniques or data protection measures are used in your biobank to prevent unauthorized access to patient data? Are there special regulations for the anonymisation of data and how is it ensured that patients cannot be traced?"
a="Pseudonyms are created using specialized software such as CentraXX or REDcap to protect patient data." />
- <QaBox q="What rights do patients have in relation to their samples, and how are these rights safeguarded in your biobank?"
+ <QaBox q="What rights do patients have in relation to their samples, and how are these rights safeguarded in your biobank?"
a="Patients have the right to revoke their consent at any time, which can be done at the clinic or biobank. The trustee, acting as an intermediary, will notify BOWL and DIZ to destroy the corresponding samples or data." />
- </>
+ </>,
+ months: ""
},
{
title: "",
@@ -1133,7 +1168,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "",
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "",
@@ -1150,7 +1186,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "",
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "Prof.Dr.",
@@ -1182,7 +1219,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
<QaBox q="What are good preclinical models for CF research, in your view?" a="Preclinical models are essential for testing the safety and efficacy of any new therapy. For CF research, one of the most reliable models is the patient-derived air-liquid interface (ALI) cultures, which replicate the lung environment and are mutation-specific. Primary cultures are available through the CF Foundation (USA) and allow researchers to test therapies in a context that closely mimics the human lung. While ALI cultures are excellent models, they are also challenging to grow and require about two months to be set up properly. For earlier-stage experiments, we often use simpler cell lines that are easier to handle. These lines allow us to perform studies at molecular level, such as testing how well a therapy restores protein production. While they do not fully represent the primary epithelial environment of the lungs, they are useful for initial validation steps before moving on to more complex models like ALI cultures." />
<QaBox q="What are your thoughts on using lipid nanoparticles (LNPs) versus other delivery systems, like AAV vectors?" a="Lipid nanoparticles (LNPs) are a promising delivery system for many genetic therapies, but they have limitations. While LNPs can effectively target certain organs, such as the lungs and liver, they cannot cross the blood-brain barrier and thus unsuitable (for now) to target neuronal pathologies. For these conditions, adeno-associated viral (AAV) vectors may be more effective, as they exhibit an inherent ability to cross the blood-brain barrier. For CF specifically, we have used LNPs to deliver sup-tRNAs directly to the lungs. We teamed up with an US company that develops safe LNPs used also for vaccines. Delivery methods like intratracheal instillation—where the LNPs are introduced into the trachea—allow for targeting the lung tissue more directly, which is critical for treating CF." />
<QaBox q="How do you view prime editing compared to other gene editing technologies?" a="Prime editing is an exciting development in the field of gene editing, but it is important to recognize that no single approach is universally superior. Technologies like prime editing, CRISPR-Cas, and our own tRNA-based therapies each have their strengths and limitations. For instance, prime editing offers a highly precise method for correcting mutations directly at the DNA level, potentially providing a one-time, lifelong cure. However, our approach, which focuses on restoring mRNA translation, does not introduce permanent changes to the genome and unforeseen, also individuum-specific side effects, can be counteracted by immediate termination of the therapy. In turn, it requires continuous re-administration over time. Ultimately, the safety and efficacy of any approach must be carefully weighed. We are not yet at a point where we can definitively rank these technologies because the field is still evolving. Each approach has potential, and the choice of which to use will likely depend on the specific disease and mutation being targeted." />
- </>
+ </>,
+ months: ""
},
{
title: "",
@@ -1199,7 +1237,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "",
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "",
@@ -1216,7 +1255,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "",
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "",
@@ -1233,7 +1273,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "",
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
{
title: "",
@@ -1250,7 +1291,8 @@ export const timelinedata: Array<TimelineDatenpunkt> = [
aimofcontact: "",
insights: "",
implementation: "",
- summary: ""
+ summary: "",
+ months: ""
},
]
--
GitLab